Elsevier

The Journal of Arthroplasty

Volume 29, Issue 12, December 2014, Pages 2439-2446
The Journal of Arthroplasty

Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan

https://doi.org/10.1016/j.arth.2014.05.029Get rights and content
Under a Creative Commons license
open access

Abstract

Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000 IU (20-mg) twice daily for 11–14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P = 1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P = 1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.

Keywords

edoxaban
factor Xa inhibitor
thromboembolic events
total hip arthroplasty
enoxaparin

Cited by (0)

The Conflict of Interest statement associated with this article can be found at doi: http://dx.doi.org/10.1016/j.arth.2014.05.029.